Dosing fentanyl buccal tablet for breakthrough cancer pain: Dose titration versus proportional doses

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 963-968

  Mercadante, Sebastiano ^a,b   Gatti, Antonio ^c   Porzio, Giampiero ^d   Lo Presti, Claudio ^e   Aielli, Federica ^d   Adile, Claudio ^a   Casuccio, Alessandra ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Dose titration; Fentanyl buccal tablet; Rapid onset opioids

Indexed keywords

FENTANYL; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT SATISFACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT; TABLETS; TITRIMETRY;

EID: 84862562811     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.683112     Document Type: Article

References (23)

1. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
3. Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
4. Caraceni A, Martini C, Zecca E, et al. Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83
5. Haugen DF, Hjermstad MJ, Hagen N, et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 2010;149:476-82
6. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Cancer 2002;94:832-9
7. Kleeberg U, Filbet M, Zeppetella G. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011;11:185-90
8. Davies A, Vriens J, Kennett A, et al. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 2008;35:406-11
9. Mercadante S. Breakthrough pain: on the road again. Eur J Pain 2009;13:329-30
10. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Crit Rev Oncol Hematol, 2011;80:460-5
11. Hjermstad MJ, Fayers PM, Haugen DF, et al. European Palliative Care Research Collaborative (EPCRC). Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011;41:1073-93
12. Aronoff G, Brennan M, Pritchard D, et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005;6:305-14
13. Hagen NA, Fisher K, Victorino C, et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 2007;10:47-55
14. Mercadante S. Rapid onset opioids for breakthrough pain: titrating or not titration or not titrating, this is the question. Eur J Pain 2011(Suppl):443-8
15. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33
16. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
17. Mercadante S, Intravaia G, Villari P, et al. Intravenous morphine for episodic-breakthrough pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35:307-13
18. Mercadante S, Villari P, Ferrera P, et al. The use of opioids for breakthrough pain in an acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 2010;26:306-9
19. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27:352-9
20. Mercadante S, Ferrera P, Adile C, et al. The use of fentanyl buccal tablets in doses proportional to the doses of opioids used for background analgesia for the treatment of breakthrough cancer pain in highly tolerant cancer patients. J Pain Symptom Manage 2011;42:464-9
21. Darwish M, Kirby M, Robertson P, et al. Dose proportionality of fentanyl buccal tablets in doses ranging from 600 to 1300 mg in healthy adult subjects. A randomized, open-label, four period, crossover, single-centre study. Clin Drug Investig 2010;30:365-78
22. Hanks GW, De Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
23. Walker G, Wilcock A, Manderson C, et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003;17:219-21